Long-term cognitive impairment in older adult twins discordant for gynecologic cancer treatment

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 66 A, Issue 12, 2011, Pages 1343-1349

  Kurita, Keiko ^a   Meyerowitz, Beth E ^a   Hall, Per ^b   Gatz, Margaret ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cancer treatment; Cognitive impairment; Long term effects; Twin analysis

Indexed keywords

ANTINEOPLASTIC AGENT;

AGED; ARTICLE; COGNITIVE DEFECT; FEMALE; FEMALE GENITAL TRACT TUMOR; HUMAN; MALE; OVARY; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; REGISTER; RETROSPECTIVE STUDY; RISK; RISK FACTOR; SWEDEN; TWINS;

AGED; ANTINEOPLASTIC AGENTS; COGNITION DISORDERS; DISEASES IN TWINS; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; MALE; ODDS RATIO; OVARY; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; SWEDEN;

EID: 81055144374     PISSN: 10795006     EISSN: 1758535X     Source Type: Journal    
DOI: 10.1093/gerona/glr140     Document Type: Article

References (42)

1. Institute of Medicine and National Research Council. From Cancer Patient to Cancer Survivor: Lost in Transition; Washington, DC: The National Academies Press; 2006.
2. Hewitt M, Rowland JH, Yancik R. Cancer survivors in the United States: age, health, and disability. J Gerontol A Biol Sci Med Sci. 2003;58(1):82-91. (Pubitemid 36110060)
3. Ahles TA, Saykin AJ, Furstenberg CT, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol. 2002;20(2):485-493. (Pubitemid 34072533)
4. Brezden CB, Phillips KA, Abdolell M, Bunston T, Tannock IF. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol. 2000;18(14):2695-2701. (Pubitemid 30463551)
5. Castellon SA, Ganz PA, Bower JE, Petersen L, Abraham L, Greendale GA. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol. 2004;26(7):955-969. (Pubitemid 39577316)
6. Fan HG, Houédé-Tchen N, Yi QL, et al. Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1-and 2-year follow-up of a prospective controlled study. J Clin Oncol. 2005;23(31):8025-8032. (Pubitemid 46657404)
7. Hurria A, Rosen C, Hudis C, et al. Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study. J Am Geriatr Soc. 2006;54(6):925-931. (Pubitemid 43847029)
8. Reid-Arndt SA, Hsieh C, Perry MC. Neuropsychological functioning and quality of life during the first year after completing chemotherapy for breast cancer. Psychooncology. 2010;19(5):535-544.
9. Schagen SB, Hamburger HL, Muller MJ, Boogerd W, van Dam FS. Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function. J Neurooncol. 2001;51(2):159-165. (Pubitemid 32435496)
10. van Dam FS, Schagen SB, Muller MJ, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst. 1998;90(3):210-218. (Pubitemid 28114539)
11. Ahles TA, Saykin AJ. Breast cancer chemotherapy-related cognitive dysfunction. Clin Breast Cancer. 2002;3(Suppl):S84-S90.
12. Falleti MG, Sanfilippo A, Maruff P, Weih L, Phillips KA. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cogn. 2005;59(1):60-70. (Pubitemid 41405841)
13. Rugo HS, Ahles T. The impact of adjuvant therapy for breast cancer on cognitive function: current evidence and directions for research. Semin Oncol. 2003;30(6):749-762. (Pubitemid 38010129)
14. Stewart A, Bielajew C, Collins B, Parkinson M, Tomiak E. A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychol. 2006;20(1):76-89.
15. Ferguson RJ, Ahles TA. Low neuropsychologic performance among adult cancer survivors treated with chemotherapy. Curr Neurol Neurosci Rep. 2003;3(3):215-222. (Pubitemid 38899005)
16. Jansen CE, Miaskowski C, Dodd M, Dowling G, Kramer J. A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer. 2005;104(10):2222-2233. (Pubitemid 41579970)
17. Anderson-Hanley C, Sherman ML, Riggs R, Agocha VB, Compas BE. Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature. J Int Neuropsychol Soc. 2003;9(7):967-982. (Pubitemid 37428441)
18. Bender CM, Sereika SM, Berga SL, et al. Cognitive impairment associated with adjuvant therapy in breast cancer. Psychooncology. 2006;15(5):422-430. (Pubitemid 43826855)
19. Bender CM, Sereika SM, Brufsky AM, et al. Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. Menopause. 2007;14(6):995-998. (Pubitemid 350098658)
20. Jenkins V, Shilling V, Fallowfield L, Howell A, Hutton S. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology. 2004;13(1):61-66. (Pubitemid 38139358)
21. Paganini-Hill A, Clark LJ. Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat. 2000;64(2):165-176. (Pubitemid 32010334)
22. Nelson CJ, Lee JS, Gamboa MC, Roth AJ. Cognitive effects of hormone therapy in men with prostate cancer. Cancer. 2008;113(5):1097-1106.
23. Kreukels BP, Schagen SB, Ridderinkhof KR, et al. Effects of high-dose and conventional-dose adjuvant chemotherapy on long-term cognitive sequelae in patients with breast cancer: an electrophysiologic study. Clin Breast Cancer. 2006;7(1):67-78. (Pubitemid 43862837)
24. Baxter NN, Durham SB, Phillips KA, Habermann EB, Virning BA. Risk of dementia in older breast cancer survivors: a population-based cohort study of the association with adjuvant chemotherapy. J Am Geriatr Soc. 2009;57(3):403-411.
25. Jenkins V, Shilling V, Deutsch G, et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer. 2006;94(6):828-834.
26. Johnson BE, Patronas N, Hayes W, et al. Neurologic, computed cranial tomographic, and magnetic resonance imaging abnormalities in patients with small-cell lung cancer: further follow-up of 6-to 13-year survivors. J Clin Oncol. 1990;8(1):48-56. (Pubitemid 20032446)
27. Schagen SB, Muller MJ, Boogerd W, et al. Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol. 2002;13(9):1387-1397.
28. Vardy J, Wefel JS, Ahles T, Tannock IF, Schagen SB. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol. 2008;19(4):623-629. (Pubitemid 351461030)
29. Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer. 2004;100(11):2292-2299. (Pubitemid 38657875)
30. Cherrier MM, Borghesani PR, Shelton AL, Higano CS. Changes in neuronal activation patterns in response to androgen deprivation therapy: a pilot study. BMC Cancer. 2010;10(1):1-8.
31. Heflin LH, Meyerowitz BE, Hall P, et al. Cancer as a risk factor for long-term cognitive deficits and dementia. J Natl Cancer Inst. 2005;97(11):854-856. (Pubitemid 40909128)
32. Jenkins V, Atkins L, Fallowfield L. Does endocrine therapy for the treatment and prevention of breast cancer affect memory and cognition? Eur J Cancer. 2007;43(9):1342-1347. (Pubitemid 46874071)
33. Minisini A, Atalay G, Bottomley A, Puglisi F, Piccart M, Biganzoli L. What is the effect of systemic anticancer treatment on cognitive function? Lancet Oncol. 2004;5(5):273-282. (Pubitemid 38541579)
34. Gatz M, Reynolds C, John R, Johansson B, Mortimer JA, Pedersen NL. Telephone screening to identify potential dementia cases in a population-based sample of older adults. Int Psychogeriatr. 2002;14(3):273-289. (Pubitemid 35375542)
35. Gatz M, Reynolds C, Nikolic J, Lowe B, Karel M, Pedersen NL. An empirical test of telephone screening to identify potential dementia cases. Int Psychogeriatr. 1995;7(3):429-437.
36. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry. 1968;114(512):797-811.
37. Erkinjuntti T, Hokkanen L, Sulkava R, Palo J. The blessed dementia scale as a screening test for dementia. Int J Geriatr Psychiatry. 1988;3:267-273. (Pubitemid 19009818)
38. Phung TK, Waltoft BL, Laursen TM, et al. Hysterectomy, oophorectomy and risk of dementia: a nationwide historical cohort study. Dement Geriatr Cogn Disord. 2010;30(1):43-50.
39. Sherwin BB. Estrogen therapy: is time of initiation critical for neuroprotection? Nat Rev. 2009;5:620-627.
40. Martin GM. The 2008 American Federation for Aging Annual Research Conference: aging and cancer: two sides of the same coin? J Gerontol A Biol Sci Med Sci. 2009;64A(6):615-617.
41. Bender CM, Paraska KK, Sereika SM, Ryan CM, Berga SL. Cognitive function and reproductive hormones in adjuvant therapy for breast cancer: a critical review. J Pain Symptom Manage. 2001;21(5):407-424. (Pubitemid 32452141)
42. Tannock IF, Ahles TA, Ganz PA, van Dam FS. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol. 2004;22(11):2233-2239. (Pubitemid 41095159)